Cost Of Illness COVID-19 Inpatient Installation at the UGM Academic Hospital

Amsaline Vingky Hutahaean; Tri Murti Andayani; Anna Wahyuni Widayanti

doi:10.22146/farmaseutik.v20i3.86457

Cost Of Illness COVID-19 Inpatient Installation at the UGM Academic Hospital

https://doi.org/10.22146/farmaseutik.v20i3.86457

Amsaline Vingky Hutahaean^(1*), Tri Murti Andayani⁽²⁾, Anna Wahyuni Widayanti⁽³⁾

(1) Faculty of Pharmacy, Universitas Gadjah Mada
(2) Departemen Farmakologi dan Farmasi Klinik, Universitas Gadjah Mada
(3) Departemen Farmasetika,Universitas Gadjah Mada
(*) Corresponding Author

Abstract

COVID-19 has become a worldwide pandemic, especially in Indonesia. The high number of COVID-19 cases in Indonesia has a financial impact, as the government must shoulder the cost of dealing with it. The study aimed to determine the direct cost and total cost (cost of illness) of COVID-19 patients at RSA UGM Yogyakarta from a hospital perspective, as well as the differences in total direct cost of hospitalized COVID-19 patients based on age, gender, length of stay, severity, and comorbidity. The cross-sectional study design of the analytic observational research method is based on a hospital perspective. Data was collected retrospectively from the patient's medical record, detailed healthcare expenditure data, and patient claim files. The data was analyzed using univariate, bivariate, and multivariate methods. The study's findings requested the number of inpatient COVID-19 patients as many as 104 samples that satisfied the inclusion specifications, as well as the total direct medical costs of Rp. 2.346.150.137 with an average cost of Rp. 22.559.154 for each patient. The most expensive components were pharmaceutical and BMHP prices of Rp. 958.410.599 (40.85%) and medical support costs of Rp. 725.163.700 (30.91%). Age, length of stay, severity of comorbidities, and usage of antivirals all have an impact on direct medical costs.

Keywords: COVID-19, hospital costs, hospital perspective, hospitalization

Keywords

COVID-19, hospital costs, hospital perspective, hospitalization

References

Al Mutair, A., Layqah, L., Alhassan, B., Alkhalifah, S., Almossabeh, M., AlSaleh, T., AlSulaiman, Z., Alatiyyah, Z., Almusalami, E. M., Al-Jamea, L. H., Woodman, A., Hajissa, K., Alhumaid, S., & Rabaan, A. A. (2022). Estimated cost of treating hospitalized COVID-19 patients in Saudi Arabia. Scientific Reports, 12(1). https://doi.org/10.1038/s41598-022-26042-z Andayani, T. M. (2013). Farmakoekonomi Prinsip dan Metodologi (Vol. 1). Bursa Ilmu. Bartsch, S. M., Ferguson, M. C., McKinnell, J. A., O’shea, K. J., Wedlock, P. T., Siegmund, S. S., & Lee, B. Y. (2020). The potential health care costs and resource use associated with COVID-19 in the United States. Health Affairs, 39(6), 927–935. https://doi.org/10.1377/hlthaff.2020.00426 Budi, A. P., & Nafisah, U. (2023). PERHITUNGAN UNIT COST PADA PASIEN COVID 19 DI INSTALASI RAWAT INAP DI RS. ROEMANI MUHAMMADIYAH SEMARANG. Jurnal Ilmiah Rekam Medis Dan Informatika Kesehatan, 13(1). https://doi.org/https://doi.org/10.47701/infokes.v13i1.2530 Centers for Disease Control and Prevention. (2020). Centers for Disease Control and Prevention. Interim US guidance for risk assessment and public health management of healthcare personnel with potential exposure in a healthcare setting to patients with coronavirus disease (COVID-19). Https://Www.Cdc.Gov/Coronavirus/2019- Ncov/Hcp/Guidance-Risk-Assesment-Hcp.Html. Edoka, I., Fraser, H., Jamieson, L., Meyer-Rath, G., & Mdewa, W. (2021). Inpatient Care Costs of COVID-19 in South Africa’s Public Healthcare System. International Journal of Health Policy and Management. https://doi.org/10.34172/ijhpm.2021.24 Giusman, R., & Nurwahyun, A. (2022). Biaya Pengobatan Pasien Rawat Inap COVID-19 di Rumah Sakit X Tahun 2021. Jurnal Ekonomi Kesehatan Indonesia, 7(2). Giusman, R., & Nurwahyuni, A. (2022). BIAYA PENGOBATAN PASIEN RAWAT INAP COVID-19 DI RUMAH SAKIT X TAHUN 2021. Jurnal Ekonomi Kesehatan Indonesia, 7(2), 96. https://doi.org/10.7454/eki.v7i2.5797 Hairani, R. (2022). Kemenkes Pastikan Percepat Bayar Klaim Layanan Covid-19. Https://Rri.Co.Id/Humaniora/Kesehatan/1356988/Kemenkes-Pastikan-Percepat-Bayar-Klaim-Layanan-Covid-19. Halimbar, A., Lorensia, A., & Ramadani, D. (2023). Cost-Effectiveness Analysis Of Remdesivir And Favipiravir Therapy For The Treatment Of Covid-19 In Adult Patients At Haji Regional General Hospital, East Java Province. Jurnal Scientia, 12(1). Hirashima, T., Arai, T., Kitajima, H., Tamura, Y., Yamada, T., Hashimoto, S., Morishita, H., Minamoto, S., Kawashima, K., Kashiwa, Y., Kameda, M., Takeshita, T., Suzuki, H., Matsuoka, H., Yamaguchi, S., Tanaka, T., & Nagai, T. (2021). Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study. Journal of Infection and Chemotherapy, 27(1), 76–82. https://doi.org/10.1016/j.jiac.2020.09.022 Jin, Y. H., Cai, L., Cheng, Z. S., Cheng, H., Deng, T., Fan, Y. P., Fang, C., Huang, D., Huang, L. Q., Huang, Q., Han, Y., Hu, B., Hu, F., Li, B. H., Li, Y. R., Liang, K., Lin, L. K., Luo, L. S., Ma, J., … Wang, X. H. (2020). A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). In Military Medical Research (Vol. 7, Issue 1). BioMed Central Ltd. https://doi.org/10.1186/s40779-020-0233-6 Karyono, D. R., & Wicaksana, A. L. (2020). Current prevalence, characteristics, and comorbidities of patients with COVID-19 in Indonesia. Journal of Community Empowerment for Health, 3(2), 77. https://doi.org/10.22146/jcoemph.57325 Kemenkes. (2020). Petunjuk Teknis Klaim Penggantian Biaya Perawatan Pasien Penyakit Infeksi Emerging Tertentu Bagi Rumah Sakit yang Menyelenggarakan Pelayanan Corona Virus Disease 2019 (COVID-19). https://covid19.kemkes.go.id/download/KMK_No_HK_01_07_MENKES_238_2020_ttg_JUKNIS_Penggantian_Biaya_Pasien_Infeksi_Emerging_Tertentu.pdfhttps://covid19.kemkes.go.id/download/KMK_No_HK_01_07_MENKES_238_2020_ttg_JUKNIS_Penggantian_Biaya_Pasien_Infeksi_Emerging_Tertentu.pdf Khandehroo, M., Dorri, M., Paykani, T., Khajavi, A., Joshani-Kheibari, M., & Esmaeili, R. (2022). Direct Inpatient Cost and Payments of COVID-19 in Iran: Quantile Regression Analysis. Medical Journal of the Islamic Republic of Iran. https://doi.org/10.47176/mjiri.36.101 Klein, S. L., & Flanagan, K. L. (2016). Sex differences in immune responses. In Nature Reviews Immunology (Vol. 16, Issue 10, pp. 626–638). Nature Publishing Group. https://doi.org/10.1038/nri.2016.90 Lemeshow, S. (1997). Besar Sampel Dalam Penelitian Kesehatan (Terjemahan). Gadjah Mada University Press. Li, X. Z., Jin, F., Zhang, J.-G., Deng, Y.-F., Shu, W., Qin, J.-M., Ma, X., & Pang, Y. (2020). Treatment of coronavirus disease 2019 in Shandong, China: a cost and affordability analysis. Infectious Diseases of Poverty, 9(1), 78. https://doi.org/10.1186/s40249-020-00689-0 Liza, A. Y., Laksmitawati, D. R., Sarnianto, P., & Anggeraini, S. D. (2022). ANALISIS KLAIM PEMBIAYAAN KEMENKES DAN BIAYA RIIL RS PADA COVID-19 DI RSUD CEMPAKA PUTIH JAKARTA. Jurnal Kesehatan, 13(2), 172–186. https://doi.org/10.38165/jk.v13i2.323 Nugraha, R. R., Pratiwi, M. A., Al-Faizin, R. E., Permana, A. B., Setiawan, E., Farianty, Y., Komaryani, K., & Thabrany, H. (2022). Predicting the cost of COVID-19 treatment and its drivers in Indonesia: analysis of claims data of COVID-19 in 2020-2021. Health Economics Review, 12(1). https://doi.org/10.1186/s13561-022-00392-w Rahmawati, C., Nurbaety, B., Qiyaam, N., Dini, S., & Maftuhah, L. (2022). Cost of illness for COVID-19 inpatients in West Nusa Tenggara, Indonesia. Pharmacy Education, 22(2), 66–69. https://doi.org/10.46542/pe.2022.222.6669 Skarayadi Oskar, Ambarsundari, Vikasari Suci, Ramadhan Muhamad Syahrul, & Sutandi Tatan. (2023). COST OF ILLNESS ANALYSIS OF COVID-19 PATIENTS WITH COMORBID TYPE 2 DIABETES IN A HOSPITAL IN BANDUNG. Pharmacoscript, 6(1). WHO. (2022). WHO Coronavirus (COVID-19). https://covid19.who.int/region/searo/country/id

DOI: https://doi.org/10.22146/farmaseutik.v20i3.86457